Healthcare

For retail investors, Nanosonics presents an intriguing proposition: a proven technology company with a dominant product in one market segment that is now attempting to replicate its success in a substantially larger addressable market. This article provides a thorough examination of the company, its …

As of March 2026, the broader market has taken note of recent developments affecting Pro Medicus' growth trajectory. While the company maintains strong fundamentals and commanding market position in radiology information systems and medical imaging analytics, today's gain reflects broader sector dynamics and investor …

The company's commitment to addressing unmet medical needs in specialized patient populations has made it a significant player in theASX-listed pharmaceutical sector. Clinuvel's focus on breakthrough therapies for conditions that have traditionally lacked effective treatment options demonstrates the company's dedication to improving patient outcomes …

The recent notice from Advance Opportunities Fund becoming an initial substantial holder in March 2026 underscores the growing confidence in Osteopore's technology platform and commercial potential. This article explores the company's innovative bone regeneration solutions, the significance of the substantial holder notice, and what …

Osteopore Limited operates in the high-growth medical technology sector, specializing in the design, development, and commercialization of three-dimensional printed bioresorbable bone implants. The company's foundation rests on groundbreaking technology licensed from the National University of Singapore, one of Asia's most prestigious research institutions. This …

Mesoblast Limited (ASX:MSB) (Nasdaq:MESO)traded at A$2.08 as of 12:38 pm on March 4, 2026, marking a 3.23% gain for the session. The advance comes amid recentvolatility, with the stock still down 13.39% over the past five days.

Neuren Pharmaceuticals Limited (ASX:NEU) closed at AUD 12.69 on 3 March 2026, down AUD 1.08 or 7.84% for the session. The decline followed confirmation that partner Acadia Pharmaceuticals plans to request a re-examination of the CHMP opinion regarding trofinetide’s European marketing application.